Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.

Dawn DePaolo, Kena C. Miller, NP, Amy Whitworth, Alice Mohr, NP, Terry L. Mashtare, Jr., Gregory Wilding, Sikander Ailawadhi, MD, Swaminathan Padmanabhan, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 4844.

https://doi.org/10.1182/blood.V110.11.4844.4844

Published: 2007

Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity.

Myron S. Czuczman, MD, Marion Skipper, Alice Mohr, NP, Zale P. Bernstein, MD, Francisco J. Hernandez-Ilizaliturri, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 1369.

https://doi.org/10.1182/blood.V110.11.1369.1369

Published: 2007

Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Myron S. Czuczman, MD, Marion Skipper, RN, Alice Mohr, NP, Zale P. Bernstein, MD, Philip McCarthy, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Alban Chanan-Khan, MD

Blood (2004) 104 (11): 1396.

https://doi.org/10.1182/blood.V104.11.1396.1396

Published: 2004

Journal Articles

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Alexandra Koryzna, RN, Peter Kouides, MD, Kathleen Donohue, Alice Mohr, NP, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3463.

https://doi.org/10.1182/blood.V104.11.3463.3463

Published: 2004

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Alexandra Koryzna, RN, Kenichi Takeshita, MD, Philip McCarthy, MD, Alice Mohr, NP, Kathleen Donohue, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3476.

https://doi.org/10.1182/blood.V104.11.3476.3476

Published: 2004

NARROW

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Email alerts

ASH Publications

American Society of Hematology

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only